12/4
07:19 am
sldb
Solid Biosciences (NASDAQ:SLDB) is now covered by analysts at Needham & Company LLC. They set a "buy" rating on the stock.
High
Report
Solid Biosciences (NASDAQ:SLDB) is now covered by analysts at Needham & Company LLC. They set a "buy" rating on the stock.
12/1
04:05 pm
sldb
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/1
08:00 am
sldb
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
Medium
Report
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
11/17
08:21 am
sldb
Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101 [Yahoo! Finance]
Low
Report
Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101 [Yahoo! Finance]
11/17
08:00 am
sldb
Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101
Neutral
Report
Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101
11/11
08:00 am
sldb
Solid Biosciences to Participate at Upcoming Investor Conferences
Medium
Report
Solid Biosciences to Participate at Upcoming Investor Conferences
11/6
08:38 am
sldb
Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy [Yahoo! Finance]
Medium
Report
Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy [Yahoo! Finance]
11/6
08:00 am
sldb
Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy
Medium
Report
Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy
11/5
04:03 pm
sldb
Solid Biosciences (NASDAQ:SLDB) had its price target lowered by analysts at Citigroup Inc. from $16.00 to $14.00. They now have a "buy" rating on the stock.
Medium
Report
Solid Biosciences (NASDAQ:SLDB) had its price target lowered by analysts at Citigroup Inc. from $16.00 to $14.00. They now have a "buy" rating on the stock.
11/5
03:27 pm
sldb
Solid Biosciences (NASDAQ:SLDB) had its price target lowered by analysts at JPMorgan Chase & Co. from $13.00 to $11.00. They now have an "overweight" rating on the stock.
Low
Report
Solid Biosciences (NASDAQ:SLDB) had its price target lowered by analysts at JPMorgan Chase & Co. from $13.00 to $11.00. They now have an "overweight" rating on the stock.
11/4
04:05 pm
sldb
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
High
Report
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/4
08:42 am
sldb
Solid Biosciences (NASDAQ:SLDB) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $15.00 price target on the stock.
High
Report
Solid Biosciences (NASDAQ:SLDB) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $15.00 price target on the stock.
11/4
08:05 am
sldb
Solid Biosciences (NASDAQ:SLDB) was given a new $9.00 price target on by analysts at Barclays PLC.
High
Report
Solid Biosciences (NASDAQ:SLDB) was given a new $9.00 price target on by analysts at Barclays PLC.
11/3
04:05 pm
sldb
Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions
High
Report
Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions
10/30
08:00 am
sldb
Solid Biosciences to Participate at Upcoming Investor Conferences
Medium
Report
Solid Biosciences to Participate at Upcoming Investor Conferences
10/19
01:05 am
sldb
Solid Biosciences (NASDAQ:SLDB) was downgraded by analysts at
Wall Stree
Medium
Report
Solid Biosciences (NASDAQ:SLDB) was downgraded by analysts at
Wall Stree
10/1
04:05 pm
sldb
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/1
08:30 am
sldb
Solid Biosciences to Present at Upcoming Scientific Meetings [Yahoo! Finance]
Low
Report
Solid Biosciences to Present at Upcoming Scientific Meetings [Yahoo! Finance]
10/1
08:00 am
sldb
Solid Biosciences to Present at Upcoming Scientific Meetings
Medium
Report
Solid Biosciences to Present at Upcoming Scientific Meetings
9/25
09:02 am
sldb
Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting [Yahoo! Finance]
Medium
Report
Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting [Yahoo! Finance]
9/25
08:00 am
sldb
Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting
Low
Report
Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting
9/23
08:33 am
sldb
Kinea Bio Secures $1.1M Jain Foundation Investment and Solid Biosciences Capsid License to Advance Novel Gene Therapy for Dysferlinopathy, a Rare Neuromuscular Disease [Yahoo! Finance]
Low
Report
Kinea Bio Secures $1.1M Jain Foundation Investment and Solid Biosciences Capsid License to Advance Novel Gene Therapy for Dysferlinopathy, a Rare Neuromuscular Disease [Yahoo! Finance]
9/23
08:14 am
sldb
Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101 [Yahoo! Finance]
Low
Report
Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101 [Yahoo! Finance]
9/23
08:00 am
sldb
Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101
Low
Report
Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101